GlycoMimetics Inc. unveiled promising Phase II data for GMI-1070, its pan-selectin inhibitor for sickle cell disease, on April 15. Partnered since 2011 with Pfizer Inc., the compound offers the potential for the first drug therapy to treat vaso-occlusive crisis episodes in patients with sickle cell disease, a genetic disorder that affects more than 80,000 Americans.
In the double-blind, placebo-controlled Phase II study, the Gaithersburg, Md., biotech found that ‘1070 reduced duration of vaso-occlusive crisis (VOC),...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?